Dr. Anna M. Cervantes-Arslanian, MD

Dr. Cervantes-Arslanian practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Cervantes-Arslanian's NPI, 1548433030, was assigned on April 7, 2008. Dr. Cervantes-Arslanian graduated from Tufts University School of Medicine in 2007. Dr. Cervantes-Arslanian holds Massachusetts license 248711.

Dr. Cervantes-Arslanian's primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Cervantes-Arslanian's primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. Dr. Cervantes-Arslanian is also affiliated with Boston Medical Center. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Cervantes-Arslanian to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cervantes-Arslanian practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Cervantes-Arslanian's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Cervantes-Arslanian is licensed in Massachusetts.

CMS data shows 135 Medicare services from Dr. Cervantes-Arslanian across 2 procedure codes in 2024, for 72 Medicare patients. Medicare paid $20,888 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 72 Medicare patients who saw Dr. Cervantes-Arslanian in 2024. The largest group is 65 to 74, with 29 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 68% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cervantes-Arslanian's median patient age at 68, with 59% women.

In 2024, Dr. Cervantes-Arslanian wrote 68 Medicare Part D claims for 14 patients. 99% of them were for generic drugs. CMS names the drug for 43 of them, across 2 drugs with 11 or more claims each, at $300 in total drug cost. In 2023, CMS named 46 claims across 2 drugs.

Dr. Cervantes-Arslanian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 56 papers to Dr. Cervantes-Arslanian, published from 2014 to 2025. 2020 was the busiest year, with 13. The most frequent topics are COVID-19, SARS-CoV-2 and Pandemics. Dr. Cervantes-Arslanian has published most often in J Stroke Cerebrovasc Dis. Dr. Cervantes-Arslanian's most frequent co-authors are Charlene J. Ong, MD, Mohamad K. Abdalkader, MD and Courtney Emi Takahashi, MD.

Dmand AI links Dr. Cervantes-Arslanian to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Persian Gulf Syndrome and War-Related Injuries.

CMS Open Payments shows 1 general payment to Dr. Cervantes-Arslanian from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Allergan Inc. paid the most, $18.

Dr. Cervantes-Arslanian graduated from Tufts University School of Medicine in 2007.